BNTX News and Press, BioNTech SE From 05/03/24

2024-05-03 09:31:56 ET Summary BioNTech is a biotech company with a strong cash position and a commercial program generating cash flow, making it a promising investment opportunity. The company's pipeline includes programs targeting cancer, respiratory infections, and other diseas...

2024-05-03 09:25:51 ET Summary BioNTech is expected to report a significant decline in sales for the first quarter, mainly due to the decline in COVID vaccine revenues. The company's earnings per share is also expected to be worse compared to the previous year. Investors shoul...

2024-05-01 10:27:47 ET Summary Genmab's stock has lost over 35% of its value since December 2022 due to unfavorable arbitration cases and high spending on launching Epkinly. The company's top line is currently dominated by royalties from Darzalex, but it hopes Epkinly will contrib...

2024-05-01 08:37:31 ET More on Pfizer Is 7%-Yielding Pfizer Stock A Buy On The Dip Before Q1? Unveiling Pfizer's Potent Cocktail: Key Drivers Of Free Cash Flow Growth Pfizer's Doldrums, Just A Bad Case Of COVID-19? Pfizer beats top-line and bottom-line estima...

2024-04-27 14:11:33 ET More on Pfizer Unveiling Pfizer's Potent Cocktail: Key Drivers Of Free Cash Flow Growth Pfizer's Doldrums, Just A Bad Case Of COVID-19? Pfizer Eyeing Viking Therapeutics? A Scenario Among All The M&A Talk Pfizer gets FDA approval fo...

2024-04-25 10:56:02 ET More on GSK GSK Trades At Low Price Multiples, But Its Pipeline Needs To Improve GSK plc (GSK) TD Cowen 44th Annual Health Care Conference (Transcript) GSK Plc: An Undervalued Vaccine Behemoth That Is Resuming Growth; Buy Sanofi reporte...

2024-04-24 11:25:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron Focused Growth Fund increased 1.68% in the first quarter. The Fund underperf...

2024-04-22 14:20:23 ET Summary Hookipa Pharma is conducting a call on 04/25/24 to share lead asset HB-200's pivotal trial design.  A Phase 2a clinical update is due in 2Q'24. The company's shares closed at $0.733, with a valuation of approximately $72.53.  Positive data ...

MAINZ, Germany, April 22, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2024 on Monday, May 6, 2024. Additionally, the Company will host a conference call and we...

2024-04-19 06:45:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The Strategy outperfor...